OrthogenRx, Inc. Sustainability Profile
OrthogenRx, Inc., headquartered in the United States, is a pioneering company in the orthobiologics industry, specialising in innovative treatments for musculoskeletal conditions. Founded in 2014, OrthogenRx has rapidly established itself as a leader in the development of regenerative medicine solutions, particularly in the field of orthopaedics. The company’s flagship product, the Orthovisc® injection, is renowned for its unique formulation that provides effective relief for osteoarthritis patients. This product, along with their other offerings, showcases OrthogenRx's commitment to advancing patient care through cutting-edge technology and research. With a strong presence across major operational regions in the US, OrthogenRx has achieved significant milestones, including numerous clinical studies that underscore the efficacy of its products. The company continues to enhance its market position through a focus on quality and innovation, making it a trusted name in the orthobiologics sector.
DitchCarbon Score
How does OrthogenRx, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
OrthogenRx, Inc.'s score of 38 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
OrthogenRx, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Avanos Medical, Inc., which may influence its climate commitments and emissions reporting. As of now, OrthogenRx has not established any documented reduction targets or climate pledges. The absence of specific emissions data and reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given its relationship with Avanos Medical, Inc., any potential emissions data or climate commitments may be inherited from this parent company. However, no specific figures or targets have been provided in the available information. In summary, OrthogenRx, Inc. is currently lacking detailed emissions data and formal climate commitments, reflecting a need for further development in its sustainability initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 1,786,730 | 0,000,000 |
| Scope 2 | 12,671,090 | 00,000,000 |
| Scope 3 | - | - |
How Carbon Intensive is OrthogenRx, Inc.'s Industry?
How Carbon Intensive is OrthogenRx, Inc.'s Location?
OrthogenRx, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
OrthogenRx, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.